Search Results - hao+su

2 Results

Sort By:

Local Cancer Chemo-immunotherapy Elicit Regression of Tumors

Unmet NeedThe market size for cancer immunotherapy was worth $58.1 billion in 2018, and with a CAGR of 14.5%, it is likely to reach up to $126.9 billion by 2026. Cancer immunotherapy is an extremely interesting and attractive means of extending the lifespan of patients with certain cancers. However, only about 15% of patients with advanced-stage cancer...

Published: 7/5/2024 | Inventor(s): Honggang Cui, Feihu Wang, Hao Su

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Immuno-Oncology

Self-assembling CPT-drug Amphiphiles for Cancer Treatment

Unmet need: DNA topoisomerases have become a widely exploited chemotherapeutic drug target for the treatment of advanced cancer. Multiple classes of topoisomerase inhibitors have been marketed including camptothecin (CPT) derivatives. However, while these analogues are less toxic than CPT, they are have reduced efficacy due to their prodrug formulation,...

Published: 7/4/2024 | Inventor(s): Honggang Cui, Hao Su, Feihu Wang

Keywords(s): Cancers, Disease Indication, Drug Delivery Vehicle, Peptides/Prodrugs, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology